- •Mipomersen lowers LDL-cholesterol significantly in patients on regular lipoprotein apheresis.
- •Adverse events such as ISRs and FLSs do occur frequently and restrict clinical use.
- •Mipomersen may be considered in subjects not qualifying for PCSK9 inhibition.
Background and aims
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the european society of cardiology (ESC) and european atherosclerosis society (EAS) developed with the special contribution of the european assocciation for cardiovascular prevention & rehabilitation (EACPR).Atherosclerosis. 2016 Oct; 253: 281-344
- Lipoprotein apheresis.Curr. Opin. Lipidol. 2010; 21: 487-491
- PCSK9 inhibitors and cardiovascular events.N. Engl. J. Med. 2015; 373: 774-775
- PCSK9 inhibitors and cardiovascular events.N. Engl. J. Med. 2015; 373: 774
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.Lancet (London, Engl. 2010; 375: 998-1006
- The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1.J. Clin. Apher. 2002; 17: 38-43
- Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia.Metabolism Clin. Exp. 1998; 47: 863-868
- Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.PLoS ONE. 2012; 7: e49006
- Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.Arterioscler. Thromb. Vasc. Biol. 2015; 35: 689-699
- Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.Circulation. 2012; 126: 2283-2292
- Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy.Circulation. 2011; 124: 2202-2207
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension.Eur. Heart J. 2015; 36: 566-575
- Effects of lipoprotein apheresis on PCSK9 levels.Athersoclerosis Sup. 2015; 18: 180-186
- Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B.J. Lipid Res. 2000; 41: 1596-1603
- Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia.J. Intern. Med. 1999; 246: 75-80
- Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial.Eur. Heart J. 2012; 33: 1142-1149
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials.Lancet. 2010; 376: 1670-1681
- European atherosclerosis society consensus panel. Statin-associated muscle symptoms: impact on statin therapy–european atherosclerosis society consensus panel statement on assessment, aetiology and management.Eur. Heart J. 2015; 36: 1012-1022
- Familial hypercholesterolemia: advances in recognition and therapy.Prog. Cardiovasc Dis. 2016 Sep - Oct; 59: 125-134
- Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.Eur. Heart J. 2016 Dec 21; 37 (Epub ahead of print): 3588-3595